NEW HEARTMATE 3™

with Full MagLev™ flow technology

RESPECTS THE FLOW



THORATEC®

HeartMate 3™

with Full MagLev™

New HeartMate 3™ with Full MagLev™ flow technology

HAEMOCOMPATIBILITY MAKES THE DIFFERENCE

Full MagLev flow technology is designed to optimise haemocompatibility and reduce blood trauma through gentle blood handling.

Remarkably low incidence of key adverse events

0	0	0
Pump thrombosis[1]	Haemolysis[1]	Pump malfunctions or exchanges[1]

Excellent 30-day and 6-month survival

98%	92%
30-day survival[1]	6-month survival[1]

Study description: Single-arm, prospective, multicentre, nonblinded, nonrandomised study to evaluate the performance and safety of HeartMate 3 Left Ventricular Assist System after 6 months of support. Patients were adults with an ejection fraction ≤25% and cardiac index ≤2.2 L/min/m^2 while not on inotropes. Patients must have also met one of the following: on optimal medical management, based on current heart failure practice guidelines, for at least 45 out of the previous 60 days and were failing to respond; or in NYHA class IIIB or IV heart failure for at least 14 days AND dependent on intra-aortic balloon pump for at least 7 days; or inotrope-dependent/unable to wean from inotropes; or listed for transplant.[1]

Patient population: Fifty patients were enrolled and implanted with HeartMate 3 at 10 centres. Patients were representative of an advanced heart failure population and were a mix of bridge-to-transplant (54%) and destination therapy (46%). Twenty-six patients (52%) were in INTERMACS profiles 2 and 3, and 24 patients (48%) were in profiles 4 to 6. No patients were in profiles 1 or 7.

HeartMate 3™
with Full MagLev™

GENTLE BLOOD HANDLING

with Full MagLev™ flow technology

DESIGNED FOR HAEMOCOMPATIBILITY with the goal of minimising complications



- Rotor is completely suspended by magnetic forces, preventing surface-to-surface contact that could cause blood trauma
- Designed for:
  - –Low haemolysis
  - –Minimised blood shearing and stasis

Large, consistent blood-flow pathways

Blood-flow gaps 10 to 20 times greater than those of hydrodynamic-bearing pumps



Dimensions are approximate for illustration purposes only.

The use of a red blood cell as a measuring unit is for illustration purposes and is not meant to imply actual blood-flow quantities during operation.

Full range of operation

Provides flow from 2.5 to 10 L/min to accommodate a broad range of clinical needs

Artificial pulsatility

Designed to promote pump washing and minimise areas of stasis in the pump

HeartMate 3™
with Full MagLev™

PERFORMANCE-LEADING OUTCOMES

with HeartMate 3™

Reach significant improvements in NYHA class[1]

83% **Patients improved**
to NYHA class I or II from
NYHA class IIIB or IV at month 6
(*P* < 0.0001 compared to baseline)

Gain significant improvement in 6-minute walk distance[2]

Average 6-minute walk distance in patients implanted with HeartMate 3 (n = 36)



NYHA: New York Heart Association.

See progressive, sustained QoL improvements[1]

EQ-5D Visual Analog Scale



Mean baseline values for paired analyses were 52.4, 52.1, and 51.4 at 1, 3, and 6 months, respectively.

Confirm a favourable safety profile[1]

Adverse events through 6 months for patients implanted with HeartMate 3 (N = 50)

ADVERSE EVENTS	Number of Patients	Percentage of Patients	Number of Events
Device thrombosis	0	0%	0
Haemolysis	0	0%	0
Stroke*			
Ischaemic	4	8%	4
Haemorrhagic	2	4%	2
Bleeding requiring surgery	7	14%	8
GI bleeding	4	8%	6
Device malfunction	0	0%	0
Driveline infection	5	10%	5
Right heart failure	5	10%	5

*Includes 3 procedure-related events: 1 implant issue (difficulty engaging inflow conduit); 1 following anaphylactic shock from contrast media; 1 following transcatheter aortic valve implantation procedure.

HeartMate 3™
with Full MagLev™

Discover a better experience

- Built to the highest standards of Swiss engineering
- Designed for intrapericardial placement
- Features a thin, mechanical apical cuff lock for quick and easy pump attachment
- Incorporates a modular driveline for straightforward replacement of external portion
- Offers an advanced controller and extended battery life for simplified patient management

HeartMate 3™ treats blood with the respect that it deserves, for optimised outcomes and better patient lives.

0 Pump thrombosis[1]

0 Haemolysis[1]

0 Pump malfunctions or exchanges[1]

98% 30-day survival[1]

92% 6-month survival[1]

References: 1. Netuka I, et al. HeartMate 3 fully magnetically levitated LVAD for the treatment of advanced heart failure: results from the CE Mark Trial. Presented at 19th Annual Meeting of the Heart Failure Society of America; September 26-29, 2015; Washington, DC. **2.** Data on file. Thoratec Corporation, 2015.

THORATEC®

HeartMate 3™

with Full MagLev™